-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Makes Its Debut at CPHI Japan in Tokyo
Category:
发布时间：2025-04-10
【概要描述】
On April 9, 2025, the highly anticipated CPHI Japan pharmaceutical ingredients exhibition was grandly held at the Tokyo Big Sight in Tokyo, drawing worldwide attention to the global pharmaceutical industry. As one of the backbone enterprises spanning the entire domestic pharmaceutical industry value chain, Shijiazhuang Sihua Pharmaceutical Group showcased its signature API products and pharmaceutical packaging materials at the event.
On April 9, 2025, the highly anticipated CPHI Japan pharmaceutical ingredients exhibition was grandly held at the Tokyo Big Sight in Tokyo, drawing worldwide attention to the global pharmaceutical industry. As one of the backbone enterprises spanning the entire domestic pharmaceutical industry value chain, Shijiazhuang Sihua Pharmaceutical Group showcased its specialty API products and pharmaceutical packaging materials at the event.
According to reports, CPHI Japan is Japan’s largest and most authoritative pharmaceutical ingredients exhibition. Since its inception in 2002, it has served as an international, professional platform for exhibitors to gain insight into the latest global advances in pharmaceutical science and technology, showcase their cutting-edge products and technologies, share industry trends and market demands, and foster business collaboration and innovation, thereby establishing itself as one of the world’s leading trade fairs for pharmaceutical raw materials.
At this exhibition, the Group prominently showcased its bulk and specialty active pharmaceutical ingredients, including caffeine, azithromycin, aminophylline, theophylline, metronidazole, and nifedipine, covering both traditional core product lines and newly developed offerings in areas such as food additives, anti-infectives, cardiovascular and cerebrovascular therapies, gastrointestinal treatments, and neurological disorders. Thanks to its comprehensive product portfolio and robust international certifications that ensure quality, the Group’s API products attracted significant attention from professional visitors. During the event, both new and existing international customers from the Asia-Pacific region and Europe and North America visited the Group’s booth for discussions and exchanges, expressing their intent to deepen cooperation on API procurement.
As a subsidiary of the Group specializing in the R&D and production of pharmaceutical packaging materials, Jiangsu Bosheng Medical New Materials Co., Ltd. prominently showcased a range of products, including non-PVC multilayer co-extruded biocompatible films and infusion films, as well as butyl rubber stoppers. In response to the stringent global demands of the biopharmaceutical industry for packaging material safety, compatibility, and convenience, Bosheng Medical’s high-barrier pharmaceutical packaging—its multilayer co-extruded biocompatible film—has garnered significant interest from international customers. Leveraging its independently developed high-barrier technology and exceptional chemical stability, this product is ideally suited to meet the storage and administration requirements of high-end biologics such as antibody drugs and vaccines.
On the morning of the first day of the exhibition, the Group’s foreign trade team hosted more than 20 international clients and reached preliminary agreements on nearly 10 cooperation initiatives. “As the world’s third-largest pharmaceutical market, Japan places stringent demands on drug quality and supply-chain stability. This participation in the exhibition not only serves as a rigorous test of the Group’s technological capabilities but also represents a pivotal step in accelerating our integration into the Asia-Pacific pharmaceutical value chain,” said a spokesperson for the Group. Looking ahead, the Group will further strengthen its extensive collaboration with customers across the Asia-Pacific region, proactively enhance brand appeal and product influence, and continuously inject new momentum into the Group’s high-quality development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091